How does CMS payment policy for Medicare, Medicaid, and 340B hospitals affect biosimilar uptake? A speaker at the recent at the 2020 Specialty Therapies and Biosimilars Congress explained.
Biosimilar pricing dynamics undergo some interesting gyrations when public payer policies come into play, Molly Burich, MS, director of public policy for biosimilars and pipeline at the pharmaceutical giant Boehringer Ingelheim, said at the 2020 Specialty Therapies and Biosimilars Congress in Miami, Florida.
340B
Take the 340B drug discount program, for example. Biosimilars are treated as innovator products and are accorded “pass-through status” under 340B policy, which means 340B hospitals that use them are reimbursed at the rate of average sales price (ASP) plus 6%, rather than ASP minus 22.5%, which applies to the older, brand products the biosimilars replicate, Burich noted.
This relatively recent policy has sparked debate, as it allows 340B hospitals to potentially obtain much higher payments for biosimilars than originator brands and incentivizes them to prescribe biosimilars instead of original brands.
“Originator companies don’t like this. They have tried to get pass-through status yanked for biosimilars. They’ve argued “they’re highly similar, they’re not new products,” Burich said. “But to CMS, they’re new products, they get an ASP, and they get a new payment code. You now have this push-pull of whether a biosimilar—which is a highly similar version of an originator product—should have pass-through status.”
There’s no indication that this policy is going to change soon, however. “CMS has for the past 2 or 3 years upheld their decision on pass-through,” Burich said.
Medicaid
On the surface, mandatory manufacturer cost rebates in Medicaid apply equally to brand biologics and biosimilars, but rebate values will be higher for originator biologics that have seen price increases, based on the payment formula. This represents an obstacle for biosimilars to become established in Medicaid coverage, Burich said. “You see many originator products moving toward a 100% rebate. It’s hard to compete with free.”
Medicare Part D
Under Medicare Part D, the manufacturer pays 70% of the discount in the coverage gap, which begins after patients have spent a pre-established amount for covered drugs. This means that under Medicare, “biosimilars and brands are now treated the same, which puts them on equal footing with regard to patient cost share as well as the plan responsibility. That’s an important piece, we believe, that will drive competition when we get there, in Part D,“ she said.
Medicare Part B
There is also equal footing of a sort for biosimilars and brand drugs under Medicare Part B, Burich said. Originator biologics are issued “J codes” for payment and are paid at the rate of ASP plus 6% at the physician office and the hospital outpatient center, unless exceptions apply. Biosimilars receive “Q codes” for payment and ASP plus 6% applies for them, too.
“Until now, new biosimilars have been granted a Q code at launch. But CMS is changing that to issuing Q codes once every quarter. I’m not sure what that will mean for the market. “I think the most important thing is we want a product-specific code. We don’t want to lose the timeliness that we’ve been getting,” she said.
These issues will become more significant as the biosimilar market develops further. The year 2019 saw more biosimilar approvals and launches in the United States than in any previous year.
“We expect to see a significant pace of approvals moving forward,” she said.
Biosimilar Uptake
Etanercept (Enbrel) and adalimumab (Humira) so far have held off against biosimilar competition. There are multiple biosimilars approved for each of these products, but none have launched. That is changing, Burich said.
AbbVie has settled with virtually all biosimilar companies for adalimumab biosimilar launches that will begin in January of 2023, she said. “Enbrel remains in legal limbo around when a biosimilar can launch.”
Zarxio was the first biosimilar to launch. It is the only biosimilar that has eclipsed the originator market. Zarxio now has 54.9% of the market for filgrastim products, versus 44.8% for Neupogen. “That took them about 4-and-a-half years,” Burich noted. “Is that a successful market? The generics utilization market didn’t go to 90% in a few years either.”
Infliximab biosimilars Inflectra and Renflexis have done poorly by comparison. “Combined, those 2 have single-digit market share, which after 2 to 3 years is not a great success story. What we’re seeing depends on product, dynamics, and originator company behavior, but for people in the biosimilar space, I think we want to see more, better uptake, and quicker,” Burich said.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
April 3rd 2024Although tender systems are a common strategy to encourage biosimilar utilization across Europe, policies like automatic substitution are rarely utilized, according to a systematic review of European policies and biosimilar uptake.